Asahi Kasei Therapeutics received FDA approval for Hovilpri, its new herpes treatment acquired earlier from AiCuris Anti-Infective Cures in an almost $1 billion deal. The approval follows the buyer’s strategy of expanding infectious disease portfolios through bolt-on transactions. For the competitive landscape, the key implication is how regulatory clearance reshapes formularies and market positioning in HSV treatment, where dosing convenience and safety profile are central. The approval also highlights execution risk and reward in acquisition-led pipelines: the manufacturing, clinical completion, and regulatory strategy now convert deal economics into a tangible marketed product.